{"status":"success","data":{"title":"Bell's Palsy Treatment","slug":"bells-palsy-treatment","tags":["Valacylovir","Acyclovir","Prednisone"],"collection":["Neurology"],"content":"<h1 id=\"bell-s-palsy-treatment\">Bell&#39;s Palsy: Treatment</h1>\n<p><strong>Treatment</strong></p>\n<p>Corticosteroids, if onset within 72 hours</p>\n<ol>\n<li><strong><span class=\"drug\">Prednisone</span></strong> 60 daily x 1 week. May consider taper for days #8-10</li>\n<li><p>NNT.com: 1 in 11 were helped (to complete recovery)</p>\n<p>Controversial benefit of antivirals (at most risk difference of 7%): American Academy of Neurology (2012), JAMA (2009), and UpToDate suggest giving for severe cases such as for Grade IV and higher </p>\n</li>\n<li><p>Cochrane review (2009): No antivirals indicated. </p>\n</li>\n<li><strong><span class=\"drug\">Valacylovir</strong></span> 1000 mg TID or <strong><span class=\"drug\">Acyclovir</strong></span> 400 mg 5x daily x 1 week</li>\n<li>Also prescribe <span class=\"drug\">corticosteroids</span>, if antivirals given.</li>\n</ol>\n<p><span class=\"drug\">Artificial tears</span> in daytime and lubricating eye ointment at night to prevent corneal drying and exposure. Tape eyelid shut while asleep.</p>\n<h2 id=\"house-brackmann-grading-for-severity-of-facial-nerve-weakness\">House-Brackmann grading for severity of facial nerve weakness</h2>\n<table>\n<thead>\n<tr>\n<th>Grade</th>\n<th>Dysfunction</th>\n<th>Gross weakness</th>\n<th>At rest</th>\n<th>Motion</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>I</td>\n<td>None</td>\n<td>No weakness</td>\n<td>No weakness</td>\n<td>Normal function all groups</td>\n</tr>\n<tr>\n<td>II</td>\n<td>Mild</td>\n<td>Slight weakness noticeable on close inspection. May have very slight synkinesis</td>\n<td>Normal symmetry and tone</td>\n<td><strong>Forehead</strong>: Moderate-to-good function  <strong>Mouth</strong>: Slight asymmetry</td>\n</tr>\n<tr>\n<td>III</td>\n<td>Moderate</td>\n<td>Obvious but not disfiguring difference; noticeable but not severe synkinesis, contracture, and/or hemifacial spasm</td>\n<td>Normal symmetry and tone</td>\n<td><strong>Forehead</strong>: Slight-to-moderate movement  <strong>Mouth</strong>: Slightly weak with maximum effort</td>\n</tr>\n<tr>\n<td>IV</td>\n<td>Moderately severe</td>\n<td>Obvious weakness and/or disfiguring asymmetry</td>\n<td>Normal symmetry and tone</td>\n<td><strong>Forehead</strong>: None  <strong>Mouth</strong>: Asymmetric with maximum effort</td>\n</tr>\n<tr>\n<td>V</td>\n<td>Severe</td>\n<td>Only barely perceptible motion</td>\n<td>Asymmetry</td>\n<td><strong>Forehead</strong>: None      <strong>Mouth</strong>: Slight movement</td>\n</tr>\n<tr>\n<td>VI</td>\n<td>Total paralysis</td>\n<td>No movement</td>\n<td>Asymmetry</td>\n<td>None for all groups</td>\n</tr>\n</tbody>\n</table>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/23136264\">Gronseth GS, Paduga R; American Academy of Neurology. Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012 Nov 27;79(22):2209-13. doi: 10.1212/WNL.0b013e318275978c. Epub 2012 Nov 7.</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=19724046\">de Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VY, Nedzelski JM, Chen JM. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA. 2009 Sep 2;302(9):985-93. doi: 10.1001/jama.2009.1243.</a></li>\n<li><a href=\"https://www.ncbi.nlm.nih.gov/pubmed/19821283\">Lockhart P, Daly F, Pitkethly M, Comerford N, Sullivan F. Antiviral treatment for Bell&#39;s palsy (idiopathic facial paralysis). Cochrane Database Syst Rev. 2009 Oct 7;(4):CD001869. doi: 10.1002/14651858.CD001869.pub4.</a></li>\n</ul>\n"}}